Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Retinal Vein OcclusionMacular Oedema

Interventions

DRUG

dexamethasone intravitreal implant 0.7 mg

OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.

Trial Locations (1)

Antwerp